Gerhardt Pohl

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data

ABSTRACT Background: Obesity is highly prevalent among patients with type 2 diabetes. Unfortunately, weight gain may also be a consequence of some antidiabetic medications. Although clinical benefits of weight loss have been established, the economic consequence of weight change among patients with type 2 diabetes is unclear. Objectives: The objective was to measure 1‑year total and diabetes-related health care costs associated with weight change during the preceding 6‑month period among type 2 diabetic patients on antidiabetic therapy. Methods: Administrative claims, electronic laboratory data and medical chart information were abstracted for continuously enrolled adults with type 2 diabetes from an health maintenance organization (HMO) for the period from July 1, 1997 through October 31, 2005. To assess the economic impact of weight change, three regression models were applied to estimate the following: (1) the effect of weight change in general (one-slope model); (2) the different effects of weight gain and no weight gain(two-slope model); and (3) the different effects of weight gain and no weight gain (i.e., no change or weight loss) among obese and non-obese patients (four-slope model). Patients included in the study had a baseline weight measurement and a second weight measurement approximately 6 months later. They were also required to be on at least one antidiabetic drug therapy within 1 month around the baseline weight measurement date (index date). Based on the measured weight change, patients were classified into two groups – weight gainers and non-weight gainer. Total health care cost and diabetes-related cost were measured during the 1‑year period following the second weight measurement and were adjusted to 2004 dollars by the medical component of the Consumer Price Index (CPI). Generalized linear models with log link function and gamma distribution were applied to assess the impacts of weight change on the 1‑year total health care cost as well as 1‑year diabetes-related cost. All models controlled for patients’ baseline demographics, comorbidities, body mass index (BMI), glycosylated hemoglobin (HbA1c), and prior resource utilization. Results: The study included 458 patients, of whom 224 (48.9%) experienced minimum weight gain of 1 pound between the two weight measurements. The average 1‑year total health care cost following the second weight measure was

Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer

6382 and the diabetes-related cost was

A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)

2002. The mean total health care cost was

Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)

7260 for the weight-gainers and

Predictors of Selecting Atomoxetine Therapy for Children with Attention-Deficit—Hyperactivity Disorder

5541 for the non-weight gainers ( p = 0.046), and the mean diabetes-related cost, respectively, was

Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers:

2141 and

Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

1869 ( p = 0.006). Results from the models showed that one percentage point of weight change was positively associated with a 3.1% (

A review and characterization of the various perceptions of quality cancer care

213, p < 0.01) change in total health care cost. When weight gain and no gain were modeled separately, one percentage point of weight loss was associated with a 3.6% (

Illness-associated productivity costs among women with employer-sponsored insurance and newly diagnosed breast cancer.

256, p < 0.05) decrease in total health care cost and a 5.8% (

Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study.

131, p < 0.01) decrease in diabetes-related cost. However, one percentage point of weight gain was not associated with significant increase in either total health care or diabetes-related cost. Further, results from the model with interactions between weight change and obesity status revealed that the economic benefit of weight loss was more pronounced in the obese group (BMI ≥ 30). Log likelihood ratio tests showed that the one-slope model for total health care cost and the two-slope model for diabetes-related cost are the appropriate models of choice. Conclusions: Weight loss significantly reduced diabetes-related costs. Controlling for baseline factors in the regression model, the 1‑year total health care cost following 1% weight loss (or gain) was